Sanofi India Limited has recommended a final dividend of ₹117 per equity share of face value ₹10 for the financial year ended December 31, 2024. The dividend is subject to approval at the 69th Annual General Meeting.
Sanofi India Q4 Financial Results
The company has also announced its Q4 financial results, reporting a 33.7% YoY decline in net profit to ₹91.3 crore, compared to ₹137.7 crore in the same period last year. Meanwhile, revenue increased by 9.7% to ₹514.9 crore from ₹469.2 crore YoY.
Key Financial Highlights:
- Net Profit: ₹91.3 crore, down 33.7% YoY
- Revenue: ₹514.9 crore, up 9.7% YoY
- EBITDA: ₹118.3 crore, up 18.8% YoY
- EBITDA Margin: 23% vs 21.2% YoY
The company attributed its revenue growth to expansion in its diabetes portfolio and new Cardiovascular (CV) and Central Nervous System (CNS) partnerships.
Rodolfo Hrosz Managing Director, Sanofi India:
“In a year of significant transformation for the company, we have successfully brought to market Soliqua® – our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”
